Paper9510317
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.
Gionchetti P and 6 others. Dis Colon Rectum, 1998. Cited by 109 papers, by iCite.
Cite this record
ConductScience Library. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Papers, record 9510317. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9510317
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colitis, Ulcerative | Major topic |
| Mesalamine | Major topic |
| Proctitis | Major topic |
| Administration, Oral | |
| Administration, Rectal | |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Single-Blind Method | |
| Treatment Outcome |
Source PubMed
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 109 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42688763 | The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort. | JGH Open | 2026 | https://conductscience.org/library/papers/42688763 | PubMed |
| 41470757 | Clinical Outcomes of Oat Beta-Glucan Nutritional Intervention in Ulcerative Colitis: Case Reports of a Female and a Male Patient. | Nutrients | 2025 | https://conductscience.org/library/papers/41470757 | PubMed |
| 41216280 | Clinical features and current treatment approach to ulcerative proctitis. | Transl Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/41216280 | PubMed |
| 39561101 | Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study. | Inflamm Bowel Dis | 2025 | https://conductscience.org/library/papers/39561101 | PubMed |
| 38613425 | Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. | J Crohns Colitis | 2024 | https://conductscience.org/library/papers/38613425 | PubMed |
| 37901338 | Clinical Background Factors as Predictors of the Efficacy of 5-Aminosalicylic Acid Suppositories in Patients with Ulcerative Colitis. | Inflamm Intest Dis | 2023 | https://conductscience.org/library/papers/37901338 | PubMed |
| 37589498 | Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis. | Aliment Pharmacol Ther | 2023 | https://conductscience.org/library/papers/37589498 | PubMed |
| 36339579 | The application of Tong-fu therapeutic method on ulcerative colitis: A systematic review and meta-analysis for efficacy and safety of rhubarb-based therapy. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36339579 | PubMed |
| 36297645 | Advancements in Rectal Drug Delivery Systems: Clinical Trials, and Patents Perspective. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36297645 | PubMed |
| 34988432 | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis. | Curr Res Pharmacol Drug Discov | 2022 | https://conductscience.org/library/papers/34988432 | PubMed |
| 34543327 | Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis. | PLoS One | 2021 | https://conductscience.org/library/papers/34543327 | PubMed |
| 32646198 | Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. | Intest Res | 2020 | https://conductscience.org/library/papers/32646198 | PubMed |
| 32207688 | 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. | Turk J Gastroenterol | 2019 | https://conductscience.org/library/papers/32207688 | PubMed |
| 31768387 | Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis. | Inflamm Intest Dis | 2019 | https://conductscience.org/library/papers/31768387 | PubMed |
| 30576644 | AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30576644 | PubMed |
| 30576642 | AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30576642 | PubMed |
| 29752633 | Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/29752633 | PubMed |
| 29429045 | Evidence-based clinical practice guidelines for inflammatory bowel disease. | J Gastroenterol | 2018 | https://conductscience.org/library/papers/29429045 | PubMed |
| 28670225 | Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. | Intest Res | 2017 | https://conductscience.org/library/papers/28670225 | PubMed |
| 28542712 | Histologic scoring indices for evaluation of disease activity in ulcerative colitis. | Cochrane Database Syst Rev | 2017 | https://conductscience.org/library/papers/28542712 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9510317
GET https://conductscience.org/api/papers/v1/9510317/cited_by?page=2